Baseline Clinical Characteristics of Ambulatory Monitoring Patients According to Treatment Strategy, and Compared to Remaining, Non-Ambulatory Monitoring INVEST Patients.

<p>Data are presented as mean (SD) or number (percent).</p><p>BMI, body mass index; CABG, coronary artery bypass graft; INVEST, INternational VErapamil SR-Trandolapril STudy; LVH, left ventricular hypertrophy; PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack.</p><p>^aComparing ambulatory monitoring study patients randomized to verapamil SR- vs. atenolol-based treatment strategies, <i>P</i> value uniformly nonsignificant.</p><p>^bComparing all ambulatory monitoring INVEST study patients with remaining, non-ambulatory monitoring patients.</p><p>^cPatients taking beta-blockers within 2 weeks of randomization or taking beta-blockers for an MI that occurred in the previous 12 months were excluded from INVEST to avoid withdrawal phenomena in patients randomized to the verapamil-based treatment strategy [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122726#pone.0122726.ref031" target="_blank">31</a>].</p><p>Baseline Clinical Characteristics of Ambulatory Monitoring Patients According to Treatment Strategy, and Compared to Remaining, Non-Ambulatory Monitoring INVEST Patients.